MASLD & MASH
Key evidence-based position statements from research organizations to guide you through screening, diagnosis, and treatment of MASLD and MASH.
Clinical Care Pathway for the Risk Stratification and Management of Patients with Metabolic Dysfunction–Associated Steatotic Liver Disease
Kanwal F, Bril F, Wai-Sun Wong V, et al. Clinical Care Pathway for the Risk Stratification and Management of Patients with Metabolic Dysfunction–Associated Steatotic Liver Disease. Gastroenterology. Published online March 9, 2026. Doi:10.1053/j.gastro.2026.01.047
Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) in People with Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association
Cusi K, Abdelmalek MF, Apovian CM, Balapattabi K, Bannuru RR, Barb D, et al. Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) in People with Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association. Diabetes Care. 2025 Jul 1;48(7):1057–1082. doi: 10.2337/dci24-0094. PMID: 40434108.
ACG Clinical Guideline: Malnutrition and Nutritional Recommendations in Liver Disease
Singal, Ashwani K. MD, MS, FACG, Wong, Robert J. MD, MS, FACG, Dasarathy, Srinivasan MD, Abdelmalek, Manal F. MD, MPH, FACG; Neuschwander-Tetri, Brent A. MD, FACG, FAASLD, AGAF, FACP, et al. ACG Clinical Guideline: Malnutrition and Nutritional Recommendations in Liver Disease. The American Journal of Gastroenterology 120(5): p 950–972, May 2025. | DOI: 10.14309/ajg.0000000000003379
Semaglutide Therapy for Metabolic Dysfunction–Associated Steatohepatitis
Bansal M, Patton H, Morgan TR, et al. Semaglutide therapy for metabolic dysfunction-associated steatohepatitis: November 2025 updates to AASLD Practice Guidance. Hepatology. 2025. Doi:10.1097/HEP.0000000000001608
EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD)
European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction–associated steatotic liver disease (MASLD). J Hepatol. 2024 Sep;81(3):492–542. doi: 10.1016/j.jhep.2024.04.031. Epub 2024 Jun 7. PMID: 38851997
Resmetirom Therapy for Metabolic Dysfunction–Associated Steatotic Liver Disease
Chen VL, Morgan TR, Rotman Y, et al. Resmetirom therapy for metabolic dysfunction–associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance. Hepatology. 2024. Doi:10.1097/HEP.0000000000001081
AASLD Practice Guidance on the Clinical Assessment and Management of Nonalcoholic Fatty Liver Disease
Rinella, M.E., Neuschwander-Tetri, B.A., Siddiqui, M.S., Abdelmalek, M.F., Caldwell, S., Barb, D., Kleiner, D.E. and Loomba, R., 2023. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology, 77(5), pp.1797–1835.
American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings
Cusi K, Isaacs S, Barb D, et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract. 2022;28(5):528–562. doi:10.1016/j.eprac.2022.03.010